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Abstract
Background: Drug resistant malaria poses an increasing public health problem in Indonesia, especially
eastern Indonesia, where malaria is highly endemic. Widespread chloroquine (CQ) resistance and
increasing sulphadoxine-pyrimethamine (SP) resistance prompted Indonesia to adopt artemisinin-based
combination therapy (ACT) as first-line therapy in 2004. To help develop a suitable malaria control
programme in the district of West Sumba, the seasonal distribution of alleles known to be associated with
resistance to CQ and SP among Plasmodium falciparum isolates from the region was investigated.
Methods: Plasmodium falciparum isolates were collected during malariometric surveys in the wet and dry
seasons in 2007 using two-stage cluster sampling. Analysis of pfcrt, pfmdr1, pfmdr1 gene copy number, dhfr,
and dhps genes were done using protocols described previously.
Results and Discussion: The 76T allele of the pfcrt gene is nearing fixation in this population. Pfmdr1
mutant alleles occurred in 72.8% and 53.3%, predominantly as 1042D and 86Y alleles that are mutually
exclusive. The prevalence of amplified pfmdr1 was found 41.9% and 42.8% of isolates in the wet and dry
seasons, respectively. The frequency of dhfr mutant alleles was much lower, either as a single 108N
mutation or paired with 59R. The 437G allele was the only mutant dhps allele detected and it was only
found during dry season.
Conclusion: The findings demonstrate a slighly higher distribution of drug-resistant alleles during the wet
season and support the policy of replacing CQ with ACT in this area, but suggest that SP might still be
effective either alone or in combination with other anti-malarials.
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Background
The most widely used anti-malarial drugs, chloroquine
(CQ) and sulfadoxine-pyrimethamine (SP), are failing at
an accelerating rate in most endemic countries, including
Indonesia. In response to this situation the World Health
Organization has recommended artemisinin-based com-
bination therapy (ACT), wherein an artemisinin deriva-
tive is paired with a second partner anti-malarial drug.
This policy, however, has several limitations in resource-
poor settings where diagnostic facilities are challenged by
availability, cost, compliance and requirements for proper
monitoring [1]. In addition, the rapid spread of resistance
to currently available anti-malarials is limiting options for
ACT partner drugs.
The molecular mechanisms underlying resistance to anti-
malarial drugs have been investigated. Several single
nucleotide polymorphisms (SNPs) in a number of Plasmo-
dium falciparum genes have been associated with resist-
ance to CQ [2] and SP [3]. In addition, amplification of
the Plasmodium falciparum multi-drug resistance 1 (pfmdr1)
gene has been associated with mefloquine resistance [4].
In Indonesia CQ, SP and primaquine have been the most
widely used anti-malarial drugs. The drugs are readily
available but diagnostic facilities are poor, and as a result
their use is often inappropriate, leading to the increased
spread of resistance. Resistance to CQ was first reported in
1975, resistance to SP appeared in 1978, and by 1997
treatment failures associated with both drugs had been
documented in most provinces [5,6]. Molecular epidemi-
ology studies conducted from 2003 to 2005 in several sen-
tinel sites throughout the Indonesia archipelago indicated
widespread distribution of mutant alleles associated with
resistance to CQ resistance (pfmdr1 86Y, Plasmodium falci-
parum chloroquine resistance (pfcrt) 76T) and SP (dihydro-
folate reductase (dhfr) and dihydropteroate synthase (dhps))
[7-10]. The mutant allele associated with chloroquine
resistance, pfcrt 76T, seems to be nearly fixed among the P.
falciparum isolates collected, and pfmdr1 1042D alleles
were mainly found in the island of Flores [9].
Previous studies of the distribution of drug resistance
markers in Indonesia were not based on large-scale sys-
tematic sampling. In order to study the distribution of
drug resistance markers more systematically, samples
from a previously reported district wide study of seasonal
malaria prevalence in West Sumba was analyzed [11]. The
frequency distributions of the alleles across the villages
throughout the district of West Sumba is reported.
Methods
Study site and sampling strategy
Sumba is a member of the Lesser Sunda Archipelago,
located in the province of East Nusa Tenggara, Indonesia,
at longitude 118.9 - 119.9 East and latitude 9.3 - 9.8
South, with total population of approximately 387,000 in
2007. The study design and sampling strategy have been
described elsewhere [11]. Briefly, malariometric surveys
were conducted twice, in March 2007 (wet season) and in
August 2007 (dry season) using two-stage cluster sam-
pling. The wet season usually occur during November to
April whereas the dry season proceeds from May to Octo-
ber. Forty-five clusters (sub-villages) were chosen by prob-
ability proportional to size sampling. Within each sub-
villages, households were chosen randomly by spinning a
pointer, and were included until 100 subjects per cluster
had been enrolled. Although the same 45 clusters were
used in both surveys, no attempt was made to re-sample
the same households; instead a new random selection of
households was made within each cluster. The malaria
prevalence in West Sumba was seasonal with the parasite
rates was 6.83% and 4.95% in the wet and dry season,
respectively. The malaria infections were mostly asympto-
matic, mainly occurred among children and teenagers,
and the geometric mean parasitemia decreased with age
[11].
Data collection
In each subject, blood was collected by finger or heel prick
for thick and thin films on glass slides and for blood blots
on filter paper (Whatman, Schleicher & Schuell, Whatman
International Ltd, Maidstone, UK) for malaria diagnosis
and parasite genotyping. The study was approved by Eijk-
man Institute for Molecular Biology Research Ethics Com-
mission, scientific and ethical review boards of the Naval
Medical Research Unit #2, and by the Indonesian
National Institute of Health Research and Development.
Genomic DNA preparation
DNA was extracted from P. falciparum positive blood sam-
ples diagnosed by microscopy as well as 10% of the
malaria negative subjects, using chelex-100 ion exchanger
(SIGMA, St Louis, USA) according to a procedure
described previously [12]. DNA was either used immedi-
ately for a polymerase chain reaction (PCR) or stored at -
20°C for later analysis.
PCR amplification and genotyping of pfcrt, pfmdr1, dhfr, 
and dhps codons
Detection of the single nucleotide polymorphisms of pfcrt,
pfmdr1, dhfr, and dhps genes was performed using PCR and
restriction fragment length polymorphyms (RFLP) as
described elsewhere [3,8,9,13,14].
Pfmdr1 copy number
Pfmdr1 copy number was assessed using a Real Time PCR
method [4,15,16]. The primers and a FAM-TAMRA (6-car-
boxyfluorescein 6-carboxy-tetra-methylrhodamine)
probe specific to a conserved region of pfmdr1 and the
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primers and a VIC-TAMRA (chemical structure not
released by Applied Biosystems) probe specific to β-tubu-
lin were multiplexed so that both genes could be assayed
in the same well. PCR reactions were performed on IQ5
Biorad® and consisted of pfmdr1 probe (150 nmol/L),
pfmdr1 primers (300 nmol/L), β-tubulin probe (100 nmol/
L), β-tubulin primers (100 nmol/L), IQ Multiplex Power-
mix (1×), DNA (2-4 μL), and water up to 25 μL. The
cycling conditions were: 95°C for 15 minutes for pre
denaturation, and 50 cycles of 95°C for 15 seconds and
60°C for 1 minute. The cycle threshold (CT) was calcu-
lated with Optical System Biorad software ver. 1.0. DNA
from strains 3D7 and W2mef were included on each plate.
Pfmdr1 copy number was calculated according to the fol-
lowing formula: copy number = (Eβtubulin)CT(βtubulin)/
(Epfmdr1)CT(pfmdr1). The efficiency (E) of β-tubulin, which was
higher than that of pfmdr1, was assumed to be 2. Pfmdr1's
efficiency, relative to that of β-tubulin, was calculated for
each plate by assuming the 3D7 control has one pfmdr1
copy. The additional control, W2mef, was previously
determined to have three pfmdr1 copies [17].
Results
Distribution of pfcrt and pfmdr1 gene polymorphisms
PCR yielded 213 and 231 amplicons in 29 and 32 villages
in the wet and dry season, respectively. The pfcrt 76T allele
was found in 92.9% of the P. falciparum isolates during
the wet season and 84.9% during the dry season (Table 1).
Analysis of isolates for the pfmdr1 gene revealed the exist-
ence of mutually exclusive 86Y and 1042D mutant alleles.
The proportion of isolates carrying the 86Y allele was
41.9% in the wet season and 42.8% in the dry season and
for the 1042D allele in the proportion were 72.8% and
53.3%. The pfmdr1 mutant alleles 1034C and 1246Y were
not found in any of the isolates examined. Allelic combi-
nations of 76T (pfcrt) with 86Y (pfmdr1) were found in
23.6% of the isolates during the wet season and 24.7% in
the dry season whereas combinations of 76T (pfcrt) with
1042D (pfmdr1) were found in 6.2% and 5.5% in the wet
and dry seasons, respectively (Table 2).
Distribution of pfmdr1 copy number
Analysis of the pfmdr1 gene copy number revealed 10.1%
and 25.9% of the P. falciparum isolates in the wet and dry
seasons, respectively, harbored more than one copy
(Table 1). Of which, 72.2% in the wet and 85.7% dry sea-
sons had more than one pfmdr1 gene copy number com-
bined with the wild type 86N allele. The proportion of
isolates that carried more than one copy number of
pfmdr1 gene combined with 1042D was 27.8% in the wet
and 14.3% in dry season, respectively. The distribution of
P. falciparum isolates that carried more than one copy
number is shown in Figure 1 in each village. The village
that has P. falciparum isolates with the highest pfmdr1 gene
copy number is Lamboya Dete.
Distribution of dhfr and dhps mutant alleles
Amplification of the dhfr gene showed that 31.5% of the
isolates carried the 108N allele in the wet season whereas
in dry season the proportion dropped to 24.7% (Figure
2). The 108T allele was not detected in any of the isolates
examined. The 59R allele was found in 25.6% and 25.4%
of the P. falciparum isolates in wet and dry seasons respec-
tively, and in most cases was paired with the 108N allele.
The other dhfr mutant alleles 16V, 50I, 51I and 164L were
not found in any of the isolates examined. Amplification
of the dhps gene revealed no mutant alleles in any of the
isolates examined during the wet season whereas in the
dry season, the 437G was found in 2.2% of the isolates.
The other dhps mutant alleles (436A, 540E, 581G and
613S/T) were not detected in any of the isolates examined.
Distribution of parasite haplotypes by village
The pattern of the parasite haplotype found in the wet and
dry season is shown in Table 3. The P. falciparum isolates
that carried wildtype alleles of the pfcrt, pfmdr1, dhfr and
dhps genes, simultaneously were only found in two sub-
jects during dry season in two remote villages of Hoha
Wungo (Kodi sub-district) and Lamboya Dete (Lamboya
sub-district). On the contrary, due to the very low distri-
bution of mutant alleles of dhps gene, we only found two
Table 1: Prevalence of pfcrt, pfmdr1 genes and pfmdr1 copy number among the isolates of P. falciparum in West Sumba District in dry 
and wet seasons
Gene Allele Prevalence (%)
Wet Season Dry Season
Pfcrt 76T 92.9 (198/213*) 84.9 (147/174)
Pfmdr1 copy number > 1.5 - 10.1 (18/178) 25.9 (14/54)
Pfmdr1 86Y 41.9 (55/131) 42.8 (27/63)
1034C 0 (0/191) 0 (0/191)
1042D 72.8 (139/191) 53.3 (96/180)
1246Y 0 (0/191) 0 (0/191)
* Number in bracket indicates samples examined
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isolates that carried simoultaneous mutant alleles in the
four gene during the dry season.
Discussion
Molecular analysis of the P. falciparum isolates collected
throughout the district of West Sumba indicated that the
76T allele of the pfcrt gene, a molecular marker for CQ
resistance, has almost gone to fixation in the local popu-
lation. Furthermore, nearly half of isolates also simultane-
ously carried pfmdr1 mutant alleles, either as 86Y or
1042D (Figure 2). Five mutant alleles of the pfmdr1 gene
have been implicated in CQ resistance: 86Y, 184F, 1032C,
Table 2: Prevalence of allelic combinations associated with CQ and SP resistance among isolates of P. falciparum in West Sumba 
District in dry and wet seasons
Allelic Combination Prevalence (%)
Wet Season Dry Season
CQ Resistance 76T + 86 Y 23.6 (41/174*) 24.7 (24/174)
76T + 1042D 6.2 (11/178) 5.5 (3/54)
SP Resistance 108N/T + 51I + 59R 0 (99) 0 (73)
437G + 540E 0 (92) 0 (92)
* Number in bracket indicates samples examined
Distribution of pfmdr1 gene copy number in the wet and dry seasons in West Sumba DistrictFigure 1
Distribution of pfmdr1 gene copy number in the wet and dry seasons in West Sumba District.
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1042D and 1246Y. Of these, 86Y and 1042D are com-
monly found throughout Asia and Oceania whereas the
1032C and 1246N alleles are typical in P. falciparum iso-
lates of Latin American origin [18,19]. In Indonesia, the
86Y allele is more prevalent in western provinces whereas
the 1042D allele dominates in the east. Interestingly,
these alleles were found to be mutually exclusive [9].
These findings endorse abandonment of CQ as the first-
line treatment of uncomplicated P. falciparum in the dis-
trict of West Sumba.
Previous data in Africa suggest an associaton between
amodiaquine (AQ) treatment failure and parasite isolates
carrying a combination of pfcrt 76T and pfmdr1 86Y alleles
[19,20]. In this study P. falciparum isolates frequently car-
ried the allelic combination of pfcrt 76T and pfmdr1 86Y,
but previous study showed artesunate (AS) and AQ com-
bination therapy to be highly effective [10]. This finding
suggests that the parasite haplotype 76T and pfmdr1 86N
is still sensitive to AQ treatment, particularly in combina-
tion with AS. Otherwise, the high efficacy of AQ might be
associated with the absence of 1246Y allele of the pfmdr1
in any of the isolates examined. Previous studies found
out the selection of pfmdr1 1246Y alleles following AQ
treatment [21-23].
In the present study, the distribution of the Pfcrt 76T,
pfmdr1 86Y, dhfr 108N and dhfr 59R alleles were slightly
higher in the wet season (Figure 2). It may be suggested
that this overrepresentation of the drug-resistant alleles
may reflect relatively higher drug pressure during in the
wet season. This suggestion is supported by the fact that
the wild type P. falciparum isolates that is found during the
dry season.
Analysis of the pfmdr1 gene copy number revealed over
10% and 25% of the P. falciparum isolates harbor more
than one copy in wet and dry season, respectively. This
finding is similar to results in Thailand where the increase
in the pfmdr1 gene copy number was associated with
resistance to mefloquine and lumefantrine [4]. This find-
ing may indicate that mefloquine and lumefantrine,
which are currently used as partner drugs for artesunate
and arthemeter, may not be suitable for use in Sumba.
Previous studies also reported that increased in copy
number of the pfmdr1 gene is more often usually paired
with wildtype 86N allele in comparison to the mutant
86Y [4,19]. This phenomenon is also observed in this
study where the 1042D was the most common pfmdr1
allele found. The increase in pfmdr1 copy number was
more often found along with either 86N or 1042N in
comparison to 86Y of 1042D. The findings indicate that
Distribution of anti-malarial drug-resistant alleles in the wet and dry seasons in West Sumba DistrictFigure 2
Distribution of anti-malarial drug-resistant alleles in the wet and dry seasons in West Sumba District. The 437G 
is the only mutant allele of the dhps gene found in this study and it was found in dry season.
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under CQ pressure the parasite may undertake either the
pfmdr1 gene amplification or mutations, and that the
former usually takes place earlier as indicated in the previ-
ous study [24].
The proportion of isolates carrying mutant alleles of the
dhfr and dhps gene are relatively small in comparison to
the P. falciparum isolates collected from the other parts of
Indonesia [7-9]. For the dhfr gene, the majority of isolates
carried the double mutation 108N+59R, whereas for dhps
only two isolates carried the 437G allele. It follows that
the use of SP as an interim alternative option to AS-AQ
could be considered in this area, as the majority of the P.
falciparum isolates are likely still sensitive to the drug.
Treatment failure with SP in Africa is associated with the
presence of quintuple mutations in dhfr and dhps genes,
respectively [25].
This study shows that the determining mutant allele asso-
ciated with CQ resistance is nearly fixed in the parasite
population found in the district of West Sumba. A high
prevalence of pfmdr1 mutant alleles was also found, rein-
forcing that CQ should no longer be used in this area.
Except for the mutant dhps 437G allele which was only
detected in two subjects during dry season, the distribu-
tion of the other drug-resistant alleles is slightly higher in
the wet season. In addition, the increasing number of P.
falciparum isolates carrying more than one copy number
of pfmdr1 limit candidate partner drugs for artemisinin as
this mutation is associated with resistance to mefloquine
and lumefantrine, two of the compounds that are cur-
rently used in ACT. However, the relatively low prevalence
of mutant alleles in the dhfr and dhps genes is encouraging
for future ACT formulations in this area.
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